Ultragenyx Faces Shareholder Class Action Lawsuit
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Should l Buy RARE?
Source: Globenewswire
- Lawsuit Background: Ultragenyx Pharmaceutical Inc. is facing a shareholder class action lawsuit for allegedly issuing false and misleading statements regarding its Phase III Orbit and Cosmic studies, which could significantly impact the company's reputation and stock price.
- Investor Losses: The lawsuit targets investors who purchased Ultragenyx shares between August 3, 2023, and December 26, 2025, encouraging those who experienced significant losses to contact legal counsel, potentially leading to increased participation in the lawsuit.
- Legal Representation: Holzer & Holzer, LLC, a highly regarded law firm in securities litigation, focuses on providing vigorous legal support to shareholders, which may have far-reaching implications for Ultragenyx's future legal liabilities.
- Lawsuit Deadline: Investors must apply to be appointed lead plaintiff by April 6, 2026, and this time constraint may affect the level of participation and outcomes of the lawsuit, further influencing Ultragenyx's market performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RARE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RARE
Wall Street analysts forecast RARE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RARE is 61.65 USD with a low forecast of 35.00 USD and a high forecast of 120.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
18 Analyst Rating
17 Buy
1 Hold
0 Sell
Strong Buy
Current: 24.690
Low
35.00
Averages
61.65
High
120.00
Current: 24.690
Low
35.00
Averages
61.65
High
120.00
About RARE
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ultragenyx Reports Long-Term Data on UX111 for Sanfilippo Syndrome
- Clinical Trial Results: Ultragenyx announced long-term data for UX111, showing a significant 23.2-point improvement (p<0.0001) in Bayley-III cognitive raw scores for 17 patients under two years old compared to natural history data during 24-60 months, indicating substantial efficacy of the gene therapy in enhancing cognitive function.
- Functional Improvements: In addition to cognitive gains, caregiver-reported outcomes using Vineland 3 demonstrated comparable improvements in communication, motor, and personal subdomains, further validating the clinical benefits of UX111.
- Biomarker Enhancements: As of the September 2025 cutoff, the median reduction in cerebrospinal fluid heparan sulfate (CSF-HS) was 63.98% (p<0.001), with 88.2% of treated children achieving a 50% or greater reduction, underscoring the treatment's effectiveness.
- FDA Application Progress: These long-term data have been included in the resubmitted Biologics License Application (BLA), with the company anticipating an accelerated review by the FDA, expected to conclude in the third quarter of 2026, which could significantly enhance UX111's market prospects.
See More
Ultragenyx Faces Shareholder Class Action Lawsuit
- Lawsuit Background: Ultragenyx Pharmaceutical Inc. is facing a shareholder class action lawsuit for allegedly issuing false and misleading statements regarding its Phase III Orbit and Cosmic studies, which could significantly impact the company's reputation and stock price.
- Investor Losses: The lawsuit targets investors who purchased Ultragenyx shares between August 3, 2023, and December 26, 2025, encouraging those who experienced significant losses to contact legal counsel, potentially leading to increased participation in the lawsuit.
- Legal Representation: Holzer & Holzer, LLC, a highly regarded law firm in securities litigation, focuses on providing vigorous legal support to shareholders, which may have far-reaching implications for Ultragenyx's future legal liabilities.
- Lawsuit Deadline: Investors must apply to be appointed lead plaintiff by April 6, 2026, and this time constraint may affect the level of participation and outcomes of the lawsuit, further influencing Ultragenyx's market performance.
See More
Ultragenyx Faces Class Action Lawsuit Over Stock Misrepresentation
- Class Action Initiation: Robbins Geller law firm announces a class action lawsuit against Ultragenyx Pharmaceutical, representing stock purchasers from August 3, 2023, to December 26, 2025, alleging violations of the Securities Exchange Act by top executives.
- False Statement Allegations: The lawsuit claims that Ultragenyx misled investors by failing to disclose risks associated with the Phase III Orbit study, where patients did not achieve a statistically significant reduction in annualized fracture rates, impacting stock price perception.
- Stock Price Plunge: Following the announcement on July 9, 2025, and December 29, 2025, regarding the failure to achieve statistical significance in study results, Ultragenyx's stock fell over 25% and 42% respectively, indicating a severe loss of investor confidence.
- Investor Rights Protection: Under the Private Securities Litigation Reform Act, any investor who purchased Ultragenyx stock during the class period can seek to be appointed as lead plaintiff, ensuring their rights are represented in the lawsuit.
See More
Ultragenyx Pharmaceutical Accused of Misleading Investors
- Class Action Filed: Robbins LLP has initiated a class action against Ultragenyx Pharmaceutical (NASDAQ: RARE) on behalf of all investors who purchased shares between August 3, 2023, and December 26, 2025, indicating strong investor concern over potential misleading actions by the company.
- Study Results Failure: The complaint alleges that Ultragenyx misrepresented the efficacy of setrusumab in its Phase III Orbit and Cosmic studies, claiming it would significantly reduce annualized fracture rates in Osteogenesis Imperfecta patients, but ultimately failed to achieve statistical significance, leading to a sharp decline in investor confidence.
- Stock Price Plunge: Following the announcement of study failures on December 29, 2025, Ultragenyx's stock price plummeted from $34.19 per share on December 26 to $19.72 on December 29, marking a staggering 42.32% drop in just one day, reflecting the market's pessimistic outlook on the company's future.
- Investor Rights Protection: Robbins LLP encourages investors interested in serving as lead plaintiffs in the class action to reach out, demonstrating the firm's commitment to protecting shareholder rights and holding companies accountable for their actions.
See More
Ultragenyx Faces Class Action Lawsuit Allegations
- Lawsuit Background: Robbins Geller Rudman & Dowd LLP announces a class action lawsuit against Ultragenyx Pharmaceutical Inc., representing purchasers of its common stock from August 3, 2023, to December 26, 2025, alleging violations of the Securities Exchange Act of 1934 by its executives.
- False Statement Allegations: The lawsuit claims that Ultragenyx misled investors regarding the statistical significance of fracture rates in its Phase III Orbit study, resulting in stock price declines of over 25% and 42% in July and December 2025, respectively, as the market reacted to the news.
- Impact of Study Failures: On December 29, 2025, Ultragenyx revealed that both its Orbit and Cosmic studies failed to achieve statistical significance against primary endpoints, raising further doubts about its product development capabilities and potentially affecting future financing and investor confidence.
- Investor Rights Protection: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Ultragenyx stock during the class period can seek to be appointed as lead plaintiff, representing other shareholders in pursuit of potential recovery, highlighting the importance of protecting investor rights.
See More
Ultragenyx Faces Class Action Lawsuit Impacting Stock Price
- Class Action Initiated: Ultragenyx Pharmaceutical Inc. is facing a class action lawsuit for allegedly providing misleading information to investors regarding its stock transactions between August 3, 2023, and December 26, 2025, which could lead to significant legal liabilities for the company.
- Stock Price Plummets: Following the announcement on December 29, 2025, that its Phase III Orbit and Cosmic studies failed to meet primary endpoints, Ultragenyx's stock price dropped dramatically from $34.19 to $19.72, a staggering 42.32% decline in a single day, reflecting a pessimistic market sentiment towards the company's future.
- Study Results Disappoint: The company's studies failed to demonstrate that setrusumab effectively reduces fracture rates despite increasing bone density, contrasting sharply with management's previous optimistic claims, which may undermine future investor confidence.
- Investor Advocacy Call: Levi & Korsinsky LLP is urging RARE shareholders to step forward before the April 6, 2026 deadline to seek lead plaintiff status, emphasizing the importance of investor rights and the challenges to corporate governance.
See More
Ultragenyx Reports Long-Term Data on UX111 for Sanfilippo Syndrome
- Clinical Trial Results: Ultragenyx announced long-term data for UX111, showing a significant 23.2-point improvement (p<0.0001) in Bayley-III cognitive raw scores for 17 patients under two years old compared to natural history data during 24-60 months, indicating substantial efficacy of the gene therapy in enhancing cognitive function.
- Functional Improvements: In addition to cognitive gains, caregiver-reported outcomes using Vineland 3 demonstrated comparable improvements in communication, motor, and personal subdomains, further validating the clinical benefits of UX111.
- Biomarker Enhancements: As of the September 2025 cutoff, the median reduction in cerebrospinal fluid heparan sulfate (CSF-HS) was 63.98% (p<0.001), with 88.2% of treated children achieving a 50% or greater reduction, underscoring the treatment's effectiveness.
- FDA Application Progress: These long-term data have been included in the resubmitted Biologics License Application (BLA), with the company anticipating an accelerated review by the FDA, expected to conclude in the third quarter of 2026, which could significantly enhance UX111's market prospects.
See More
Ultragenyx Faces Shareholder Class Action Lawsuit
- Lawsuit Background: Ultragenyx Pharmaceutical Inc. is facing a shareholder class action lawsuit for allegedly issuing false and misleading statements regarding its Phase III Orbit and Cosmic studies, which could significantly impact the company's reputation and stock price.
- Investor Losses: The lawsuit targets investors who purchased Ultragenyx shares between August 3, 2023, and December 26, 2025, encouraging those who experienced significant losses to contact legal counsel, potentially leading to increased participation in the lawsuit.
- Legal Representation: Holzer & Holzer, LLC, a highly regarded law firm in securities litigation, focuses on providing vigorous legal support to shareholders, which may have far-reaching implications for Ultragenyx's future legal liabilities.
- Lawsuit Deadline: Investors must apply to be appointed lead plaintiff by April 6, 2026, and this time constraint may affect the level of participation and outcomes of the lawsuit, further influencing Ultragenyx's market performance.
See More
Ultragenyx Faces Class Action Lawsuit Over Stock Misrepresentation
- Class Action Initiation: Robbins Geller law firm announces a class action lawsuit against Ultragenyx Pharmaceutical, representing stock purchasers from August 3, 2023, to December 26, 2025, alleging violations of the Securities Exchange Act by top executives.
- False Statement Allegations: The lawsuit claims that Ultragenyx misled investors by failing to disclose risks associated with the Phase III Orbit study, where patients did not achieve a statistically significant reduction in annualized fracture rates, impacting stock price perception.
- Stock Price Plunge: Following the announcement on July 9, 2025, and December 29, 2025, regarding the failure to achieve statistical significance in study results, Ultragenyx's stock fell over 25% and 42% respectively, indicating a severe loss of investor confidence.
- Investor Rights Protection: Under the Private Securities Litigation Reform Act, any investor who purchased Ultragenyx stock during the class period can seek to be appointed as lead plaintiff, ensuring their rights are represented in the lawsuit.
See More
Ultragenyx Pharmaceutical Accused of Misleading Investors
- Class Action Filed: Robbins LLP has initiated a class action against Ultragenyx Pharmaceutical (NASDAQ: RARE) on behalf of all investors who purchased shares between August 3, 2023, and December 26, 2025, indicating strong investor concern over potential misleading actions by the company.
- Study Results Failure: The complaint alleges that Ultragenyx misrepresented the efficacy of setrusumab in its Phase III Orbit and Cosmic studies, claiming it would significantly reduce annualized fracture rates in Osteogenesis Imperfecta patients, but ultimately failed to achieve statistical significance, leading to a sharp decline in investor confidence.
- Stock Price Plunge: Following the announcement of study failures on December 29, 2025, Ultragenyx's stock price plummeted from $34.19 per share on December 26 to $19.72 on December 29, marking a staggering 42.32% drop in just one day, reflecting the market's pessimistic outlook on the company's future.
- Investor Rights Protection: Robbins LLP encourages investors interested in serving as lead plaintiffs in the class action to reach out, demonstrating the firm's commitment to protecting shareholder rights and holding companies accountable for their actions.
See More
Ultragenyx Faces Class Action Lawsuit Allegations
- Lawsuit Background: Robbins Geller Rudman & Dowd LLP announces a class action lawsuit against Ultragenyx Pharmaceutical Inc., representing purchasers of its common stock from August 3, 2023, to December 26, 2025, alleging violations of the Securities Exchange Act of 1934 by its executives.
- False Statement Allegations: The lawsuit claims that Ultragenyx misled investors regarding the statistical significance of fracture rates in its Phase III Orbit study, resulting in stock price declines of over 25% and 42% in July and December 2025, respectively, as the market reacted to the news.
- Impact of Study Failures: On December 29, 2025, Ultragenyx revealed that both its Orbit and Cosmic studies failed to achieve statistical significance against primary endpoints, raising further doubts about its product development capabilities and potentially affecting future financing and investor confidence.
- Investor Rights Protection: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Ultragenyx stock during the class period can seek to be appointed as lead plaintiff, representing other shareholders in pursuit of potential recovery, highlighting the importance of protecting investor rights.
See More
Ultragenyx Faces Class Action Lawsuit Impacting Stock Price
- Class Action Initiated: Ultragenyx Pharmaceutical Inc. is facing a class action lawsuit for allegedly providing misleading information to investors regarding its stock transactions between August 3, 2023, and December 26, 2025, which could lead to significant legal liabilities for the company.
- Stock Price Plummets: Following the announcement on December 29, 2025, that its Phase III Orbit and Cosmic studies failed to meet primary endpoints, Ultragenyx's stock price dropped dramatically from $34.19 to $19.72, a staggering 42.32% decline in a single day, reflecting a pessimistic market sentiment towards the company's future.
- Study Results Disappoint: The company's studies failed to demonstrate that setrusumab effectively reduces fracture rates despite increasing bone density, contrasting sharply with management's previous optimistic claims, which may undermine future investor confidence.
- Investor Advocacy Call: Levi & Korsinsky LLP is urging RARE shareholders to step forward before the April 6, 2026 deadline to seek lead plaintiff status, emphasizing the importance of investor rights and the challenges to corporate governance.
See More
